Financhill
Sell
45

VSTM Quote, Financials, Valuation and Earnings

Last price:
$4.02
Seasonality move :
9.25%
Day range:
$4.19 - $4.55
52-week range:
$2.10 - $14.22
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
16.88x
Volume:
1.8M
Avg. volume:
1.1M
1-year change:
-46.01%
Market cap:
$186.7M
Revenue:
--
EPS (TTM):
-$3.20

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
VSTM
Verastem
$44.4K -$0.82 -- -28.48% --
APLT
Applied Therapeutics
-- -$0.16 -76.55% -43.43% $6.80
IBIO
iBio
-- -$0.46 -100% -89.82% --
NBY
NovaBay Pharmaceuticals
$2.6M -$0.31 -60.77% -99.16% --
PTN
Palatin Technologies
-- -$0.51 -100% -25% --
RVPH
Reviva Pharmaceuticals Holdings
-- -$0.25 -- -30.3% $15.20
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
VSTM
Verastem
$4.20 -- $186.7M -- $0.00 0% --
APLT
Applied Therapeutics
$0.88 $6.80 $102.4M -- $0.00 0% --
IBIO
iBio
$2.48 -- $22.7M -- $0.00 0% --
NBY
NovaBay Pharmaceuticals
$0.53 -- $2.6M -- $0.00 0% 0.06x
PTN
Palatin Technologies
$0.97 -- $18.9M -- $0.00 0% --
RVPH
Reviva Pharmaceuticals Holdings
$1.34 $15.20 $44.6M -- $0.00 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
VSTM
Verastem
50.52% 0.043 40.34% 3.10x
APLT
Applied Therapeutics
-- 4.461 -- 1.00x
IBIO
iBio
4.41% 6.097 5.41% 3.89x
NBY
NovaBay Pharmaceuticals
4.54% 0.704 1.51% 0.75x
PTN
Palatin Technologies
-- -0.872 -- 0.99x
RVPH
Reviva Pharmaceuticals Holdings
-- 2.029 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
VSTM
Verastem
-- -$37M -78.01% -120.71% -71.18% -$23.8M
APLT
Applied Therapeutics
-- -$29.7M -790.52% -797.82% -24379.51% -$23.3M
IBIO
iBio
-- -$4.1M -90.99% -148.3% -1820.57% -$3.7M
NBY
NovaBay Pharmaceuticals
$1.6M -$1.1M -334.47% -461.38% -44% -$2.1M
PTN
Palatin Technologies
$350K -$7.8M -- -- -2356.3% -$7M
RVPH
Reviva Pharmaceuticals Holdings
-- -$8.5M -- -- -- -$4.2M

Verastem vs. Competitors

  • Which has Higher Returns VSTM or APLT?

    Applied Therapeutics has a net margin of -82.56% compared to Verastem's net margin of -56222.13%. Verastem's return on equity of -120.71% beat Applied Therapeutics's return on equity of -797.82%.

    Company Gross Margin Earnings Per Share Invested Capital
    VSTM
    Verastem
    -- -$0.60 $80.9M
    APLT
    Applied Therapeutics
    -- -$0.48 $5.9M
  • What do Analysts Say About VSTM or APLT?

    Verastem has a consensus price target of --, signalling upside risk potential of 165.2%. On the other hand Applied Therapeutics has an analysts' consensus of $6.80 which suggests that it could grow by 672.64%. Given that Applied Therapeutics has higher upside potential than Verastem, analysts believe Applied Therapeutics is more attractive than Verastem.

    Company Buy Ratings Hold Ratings Sell Ratings
    VSTM
    Verastem
    6 0 0
    APLT
    Applied Therapeutics
    4 2 0
  • Is VSTM or APLT More Risky?

    Verastem has a beta of 0.221, which suggesting that the stock is 77.906% less volatile than S&P 500. In comparison Applied Therapeutics has a beta of 1.765, suggesting its more volatile than the S&P 500 by 76.451%.

  • Which is a Better Dividend Stock VSTM or APLT?

    Verastem has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Applied Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verastem pays -- of its earnings as a dividend. Applied Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VSTM or APLT?

    Verastem quarterly revenues are $10M, which are larger than Applied Therapeutics quarterly revenues of $122K. Verastem's net income of -$24M is higher than Applied Therapeutics's net income of -$68.6M. Notably, Verastem's price-to-earnings ratio is -- while Applied Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verastem is -- versus -- for Applied Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VSTM
    Verastem
    -- -- $10M -$24M
    APLT
    Applied Therapeutics
    -- -- $122K -$68.6M
  • Which has Higher Returns VSTM or IBIO?

    iBio has a net margin of -82.56% compared to Verastem's net margin of -4444.57%. Verastem's return on equity of -120.71% beat iBio's return on equity of -148.3%.

    Company Gross Margin Earnings Per Share Invested Capital
    VSTM
    Verastem
    -- -$0.60 $80.9M
    IBIO
    iBio
    -- -$0.46 $22.3M
  • What do Analysts Say About VSTM or IBIO?

    Verastem has a consensus price target of --, signalling upside risk potential of 165.2%. On the other hand iBio has an analysts' consensus of -- which suggests that it could grow by 45.16%. Given that Verastem has higher upside potential than iBio, analysts believe Verastem is more attractive than iBio.

    Company Buy Ratings Hold Ratings Sell Ratings
    VSTM
    Verastem
    6 0 0
    IBIO
    iBio
    0 0 0
  • Is VSTM or IBIO More Risky?

    Verastem has a beta of 0.221, which suggesting that the stock is 77.906% less volatile than S&P 500. In comparison iBio has a beta of -3.237, suggesting its less volatile than the S&P 500 by 423.713%.

  • Which is a Better Dividend Stock VSTM or IBIO?

    Verastem has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verastem pays -- of its earnings as a dividend. iBio pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VSTM or IBIO?

    Verastem quarterly revenues are $10M, which are larger than iBio quarterly revenues of $175K. Verastem's net income of -$24M is lower than iBio's net income of -$4M. Notably, Verastem's price-to-earnings ratio is -- while iBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verastem is -- versus -- for iBio. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VSTM
    Verastem
    -- -- $10M -$24M
    IBIO
    iBio
    -- -- $175K -$4M
  • Which has Higher Returns VSTM or NBY?

    NovaBay Pharmaceuticals has a net margin of -82.56% compared to Verastem's net margin of -49.65%. Verastem's return on equity of -120.71% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    VSTM
    Verastem
    -- -$0.60 $80.9M
    NBY
    NovaBay Pharmaceuticals
    65.26% -$0.60 $1.1M
  • What do Analysts Say About VSTM or NBY?

    Verastem has a consensus price target of --, signalling upside risk potential of 165.2%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 602.96%. Given that NovaBay Pharmaceuticals has higher upside potential than Verastem, analysts believe NovaBay Pharmaceuticals is more attractive than Verastem.

    Company Buy Ratings Hold Ratings Sell Ratings
    VSTM
    Verastem
    6 0 0
    NBY
    NovaBay Pharmaceuticals
    0 0 0
  • Is VSTM or NBY More Risky?

    Verastem has a beta of 0.221, which suggesting that the stock is 77.906% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

  • Which is a Better Dividend Stock VSTM or NBY?

    Verastem has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verastem pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VSTM or NBY?

    Verastem quarterly revenues are $10M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Verastem's net income of -$24M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Verastem's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verastem is -- versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VSTM
    Verastem
    -- -- $10M -$24M
    NBY
    NovaBay Pharmaceuticals
    0.06x -- $2.4M -$1.2M
  • Which has Higher Returns VSTM or PTN?

    Palatin Technologies has a net margin of -82.56% compared to Verastem's net margin of -2357.27%. Verastem's return on equity of -120.71% beat Palatin Technologies's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    VSTM
    Verastem
    -- -$0.60 $80.9M
    PTN
    Palatin Technologies
    -- -$0.39 -$111.5K
  • What do Analysts Say About VSTM or PTN?

    Verastem has a consensus price target of --, signalling upside risk potential of 165.2%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1656.38%. Given that Palatin Technologies has higher upside potential than Verastem, analysts believe Palatin Technologies is more attractive than Verastem.

    Company Buy Ratings Hold Ratings Sell Ratings
    VSTM
    Verastem
    6 0 0
    PTN
    Palatin Technologies
    0 0 0
  • Is VSTM or PTN More Risky?

    Verastem has a beta of 0.221, which suggesting that the stock is 77.906% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

  • Which is a Better Dividend Stock VSTM or PTN?

    Verastem has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verastem pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VSTM or PTN?

    Verastem quarterly revenues are $10M, which are larger than Palatin Technologies quarterly revenues of $350K. Verastem's net income of -$24M is lower than Palatin Technologies's net income of -$7.8M. Notably, Verastem's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verastem is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VSTM
    Verastem
    -- -- $10M -$24M
    PTN
    Palatin Technologies
    -- -- $350K -$7.8M
  • Which has Higher Returns VSTM or RVPH?

    Reviva Pharmaceuticals Holdings has a net margin of -82.56% compared to Verastem's net margin of --. Verastem's return on equity of -120.71% beat Reviva Pharmaceuticals Holdings's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    VSTM
    Verastem
    -- -$0.60 $80.9M
    RVPH
    Reviva Pharmaceuticals Holdings
    -- -$0.25 --
  • What do Analysts Say About VSTM or RVPH?

    Verastem has a consensus price target of --, signalling upside risk potential of 165.2%. On the other hand Reviva Pharmaceuticals Holdings has an analysts' consensus of $15.20 which suggests that it could grow by 1038.58%. Given that Reviva Pharmaceuticals Holdings has higher upside potential than Verastem, analysts believe Reviva Pharmaceuticals Holdings is more attractive than Verastem.

    Company Buy Ratings Hold Ratings Sell Ratings
    VSTM
    Verastem
    6 0 0
    RVPH
    Reviva Pharmaceuticals Holdings
    3 1 0
  • Is VSTM or RVPH More Risky?

    Verastem has a beta of 0.221, which suggesting that the stock is 77.906% less volatile than S&P 500. In comparison Reviva Pharmaceuticals Holdings has a beta of -0.023, suggesting its less volatile than the S&P 500 by 102.311%.

  • Which is a Better Dividend Stock VSTM or RVPH?

    Verastem has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Reviva Pharmaceuticals Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verastem pays -- of its earnings as a dividend. Reviva Pharmaceuticals Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VSTM or RVPH?

    Verastem quarterly revenues are $10M, which are larger than Reviva Pharmaceuticals Holdings quarterly revenues of --. Verastem's net income of -$24M is lower than Reviva Pharmaceuticals Holdings's net income of -$8.4M. Notably, Verastem's price-to-earnings ratio is -- while Reviva Pharmaceuticals Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verastem is -- versus -- for Reviva Pharmaceuticals Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VSTM
    Verastem
    -- -- $10M -$24M
    RVPH
    Reviva Pharmaceuticals Holdings
    -- -- -- -$8.4M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret

It’s not often that a company with the scale and…

Will Tyson Foods Stock Bounce Back?
Will Tyson Foods Stock Bounce Back?

Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…

Will Iovance Biotherapeutics Stock Bounce Back?
Will Iovance Biotherapeutics Stock Bounce Back?

Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…

Stock Ideas

Buy
64
Is AAPL Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 42x

Buy
52
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 113x

Buy
55
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Alerts

Buy
61
QMCO alert for Dec 23

Quantum [QMCO] is up 0.73% over the past day.

Sell
46
NUKK alert for Dec 23

Nukkleus [NUKK] is up 6.88% over the past day.

Sell
1
IIPR alert for Dec 23

Innovative Industrial Properties [IIPR] is down 5.35% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock